12 Month Price Forecast For CRSP
Distance to CRSP Price Forecasts
CRSP Price Momentum
๐ค Considering CRISPR (CRSP)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 16, 2025 2:20 AM UTC
CRSP Analyst Ratings & Price Targets
Based on our analysis of 35 Wall Street analysts, CRSP has a bullish consensus with a median price target of $82.00 (ranging from $32.00 to $268.00). The overall analyst rating is Buy (7.7/10). Currently trading at $49.72, the median forecast implies a 64.9% upside. This outlook is supported by 16 Buy, 12 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Terence Flynn at Morgan Stanley, suggesting a 35.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRSP Analyst Consensus
CRSP Price Target Range
Latest CRSP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRSP.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 14, 2025 | Evercore ISI Group | Liisa Bayko | Outperform | Upgrade | $99.00 |
Feb 14, 2025 | Morgan Stanley | Terence Flynn | Underweight | Maintains | $32.00 |
Feb 13, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $86.00 |
Feb 13, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $84.00 |
Feb 13, 2025 | Stifel | Benjamin Burnett | Hold | Maintains | $49.00 |
Feb 13, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $65.00 |
Feb 13, 2025 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $57.00 |
Feb 12, 2025 | Needham | Gil Blum | Buy | Reiterates | $84.00 |
Feb 12, 2025 | Truist Securities | Joon Lee | Buy | Maintains | $120.00 |
Feb 12, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $56.00 |
Feb 12, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $48.00 |
Feb 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $65.00 |
Jan 14, 2025 | Needham | Gil Blum | Buy | Reiterates | $84.00 |
Jan 7, 2025 | B of A Securities | Geoff Meacham | Buy | Maintains | $85.00 |
Dec 20, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $86.00 |
Dec 10, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $94.00 |
Nov 6, 2024 | RBC Capital | Luca Issi | Sector Perform | Reiterates | $53.00 |
Nov 6, 2024 | Needham | Gil Blum | Buy | Reiterates | $84.00 |
Nov 6, 2024 | Barclays | Gena Wang | Equal-Weight | Maintains | $55.00 |
Oct 4, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $53.00 |
Stocks Similar to Crispr Therapeutics AG
The following stocks are similar to CRISPR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Crispr Therapeutics AG (CRSP) Financial Data
Crispr Therapeutics AG has a market capitalization of $4.26B with a P/E ratio of -11.5x. The company generates $37.31M in trailing twelve-month revenue with a -215.0% profit margin.
Revenue growth is -82.3% quarter-over-quarter, while maintaining an operating margin of -181.0% and return on equity of -19.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Crispr Therapeutics AG (CRSP) Company Overview
About Crispr Therapeutics AG
Develops gene-based medicines using CRISPR technology.
The company focuses on creating gene-editing therapies for serious diseases using its proprietary CRISPR/Cas9 platform. It generates revenue through the development and commercialization of its therapeutic programs, which target various conditions including hemoglobinopathies and cancers, often in collaboration with strategic partners.
CRISPR Therapeutics AG is headquartered in Zug, Switzerland, and was incorporated in 2013. Its lead product candidate, CASGEVY, is aimed at treating transfusion-dependent beta-thalassemia and severe sickle cell disease. The company also has a diverse portfolio of investigational therapies for oncology, autoimmune diseases, and cardiovascular conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
393
CEO
Dr. Samarth Kulkarni Ph.D.
Country
Switzerland
IPO Year
2016
Website
www.crisprtx.comCrispr Therapeutics AG (CRSP) Latest News & Analysis
CRISPR Therapeutics (CRSP) stock rose over 9% following a positive quarterly earnings report released after market hours on Tuesday.
The surge in CRISPR Therapeutics' stock reflects strong investor confidence following positive quarterly earnings, indicating potential growth and profitability in the biotech sector.
CRISPR Therapeutics anticipates significant developments in 2025, including updates on CAR T products CTX112 and CTX131, and a strong cash position of $1.9 billion as of December 31, 2024.
The news highlights CRISPR Therapeutics' robust pipeline and strong financial position, indicating potential growth and innovation in gene therapies, which could drive stock performance and investor interest.
CRSP reports positive fourth-quarter results and the successful commercial launch of its CRISPR-based gene therapy, Casgevy, is underway.
Positive fourth-quarter results and a successful CRISPR therapy launch signal strong growth potential for CRSP, likely boosting investor confidence and stock performance.
CRISPR Therapeutics AG reported a quarterly loss of $0.44 per share, beating estimates of a $1.15 loss, compared to earnings of $1.10 per share in the same quarter last year.
CRISPR's smaller-than-expected loss indicates improving financial health, potentially boosting investor confidence and impacting stock performance positively.
Investing in underperforming stocks may be beneficial if recovery prospects exist; however, many lagging companies currently lack such potential.
Stocks underperforming without recovery potential can indicate poor fundamentals, increasing risk for investors. Caution is advised in selecting investments with sustainable growth prospects.
Investors will closely watch CRSP's Q4 2024 earnings call for updates on sales of Casgevy, the company's first marketed product.
Casgevy's sales performance will indicate market acceptance and revenue potential, impacting CRSP's financial outlook and investor sentiment.
Frequently Asked Questions About CRSP Stock
What is Crispr Therapeutics AG's (CRSP) stock forecast for 2025?
Based on our analysis of 35 Wall Street analysts, Crispr Therapeutics AG (CRSP) has a median price target of $82.00. The highest price target is $268.00 and the lowest is $32.00.
Is CRSP stock a good investment in 2025?
According to current analyst ratings, CRSP has 16 Buy ratings, 12 Hold ratings, and 1 Sell ratings. The stock is currently trading at $49.72. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CRSP stock?
Wall Street analysts predict CRSP stock could reach $82.00 in the next 12 months. This represents a 64.9% increase from the current price of $49.72. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Crispr Therapeutics AG's business model?
The company focuses on creating gene-editing therapies for serious diseases using its proprietary CRISPR/Cas9 platform. It generates revenue through the development and commercialization of its therapeutic programs, which target various conditions including hemoglobinopathies and cancers, often in collaboration with strategic partners.
What is the highest forecasted price for CRSP Crispr Therapeutics AG?
The highest price target for CRSP is $268.00 from at , which represents a 439.0% increase from the current price of $49.72.
What is the lowest forecasted price for CRSP Crispr Therapeutics AG?
The lowest price target for CRSP is $32.00 from Terence Flynn at Morgan Stanley, which represents a -35.6% decrease from the current price of $49.72.
What is the overall CRSP consensus from analysts for Crispr Therapeutics AG?
The overall analyst consensus for CRSP is bullish. Out of 35 Wall Street analysts, 16 rate it as Buy, 12 as Hold, and 1 as Sell, with a median price target of $82.00.
How accurate are CRSP stock price projections?
Stock price projections, including those for Crispr Therapeutics AG, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.